Corticosteroid injection and hydrodilatation

Separate the intervention from the promise

Patients may hear an injection described as anti-inflammatory, a way to “break adhesions,” or a cure. These claims are not equivalent. Corticosteroid aims to modify pain and inflammatory activity; it does not mechanically remove all capsular restriction. Hydrodilatation introduces fluid to distend the joint capsule, usually alongside local anaesthetic and often corticosteroid. Neither procedure guarantees rapid or complete recovery.

A better consent discussion defines the intended benefit and timeframe. Is the priority to reduce severe night pain, create a window for self-care and rehabilitation, or address persistent stiffness after a reasonable non-operative plan? If the intended outcome is vague, it becomes difficult to judge whether the intervention worked.

Where corticosteroid injection fits

Randomised trials and systematic reviews generally show the clearest benefit in the first weeks to a few months. This pattern is clinically relevant in a painful, high-irritability presentation where sleep and basic activity are compromised. It is less compelling as a promise of superior long-term recovery, because group differences often diminish as the natural course and other care influence outcomes.

The 2025 clinical practice guideline recommends intra-articular steroid injection for primary frozen shoulder and suggests that injection combined with physical therapy may be beneficial. “Combined” should not be interpreted as immediate forceful stretching. The rehabilitation plan should be matched to symptom response and the opportunity created by pain reduction.

This diagram is conceptual, not a prediction for an individual. Response may be rapid, delayed, small or absent. Duration of symptoms, diabetes, severity, injection technique, co-interventions and study definitions all complicate attempts to identify a single “best” timing rule.

Route, site and guidance

Glenohumeral intra-articular injection is commonly studied because the capsule and synovium are central to frozen shoulder. Subacromial injection has also been investigated, and studies do not provide a simple universal answer about the best site for every presentation. The decision should follow diagnosis, the suspected pain source, professional competence and local guidance.

Ultrasound or fluoroscopic guidance can improve the likelihood that an intra-articular injection reaches the intended location. Clinical outcome is a separate question: accurate placement may be desirable without consistently producing a large additional improvement in pain or disability compared with a well-performed landmark-guided approach. Availability, cost, operator skill, patient anatomy and the purpose of the procedure all belong in the decision.

What hydrodilatation adds

Hydrodilatation - also called hydrodistension or distension arthrography - introduces fluid into the glenohumeral joint under imaging. Protocols vary substantially. Studies use different fluid volumes, corticosteroids, local anaesthetics, approaches, pressures and definitions of capsular rupture. Some intend distension without rupture; others describe rupture as part of the procedure. Rehabilitation after the intervention also varies.

This heterogeneity matters because “hydrodilatation” is not one reproducible treatment. When a trial compares hydrodilatation containing corticosteroid with steroid injection alone, any difference may reflect distension, volume, placement, post-procedure care or chance. When both groups improve, it is easy to overattribute the result to rupture or a specific volume.

A 2023 systematic review and meta-analysis reported transient advantages for disability and passive external rotation, while emphasising uncertainty and variation between studies. Individual randomised trials have produced conflicting findings: some report an additional benefit, while others find little or no clinically important advantage over corticosteroid injection alone.

How to communicate the evidence

Risk, precautions and consent

Consent should address expected benefit, uncertainty, alternatives and material risks relevant to the patient. Details depend on the medicine, technique, setting and local governance. Common discussion points include transient post-injection pain, bruising or bleeding, infection, allergic or vasovagal reactions, skin depigmentation or subcutaneous fat change, and temporary systemic steroid effects.

Anticoagulant and antiplatelet medicines require an assessment consistent with local policy; patients should not independently stop prescribed medication. Suspected infection, local skin infection and relevant allergy require appropriate review. Repeated steroid exposure raises additional tissue and systemic considerations, so repeat treatment should not be automatic simply because the first injection gave temporary relief.

Diabetes and glucose management

Diabetes is associated with a higher likelihood of frozen shoulder and may be associated with poorer outcomes, although prognostic certainty is limited. Corticosteroid injection can cause a temporary rise in blood glucose. The size and duration vary with the person, diabetes type and control, steroid preparation and dose.

People with diabetes should receive an individual monitoring plan consistent with their diabetes care and local guidance. This may include more frequent glucose checks and clear thresholds for contacting the clinician responsible for diabetes management. The person should not be surprised by this issue after the injection has already been given.

Connecting the procedure to rehabilitation

The purpose of follow-up is not simply to measure range. Reassess the target that justified intervention: sleep, pain, dressing, work, movement confidence or capacity for rehabilitation. If pain falls, the programme can use that opportunity without assuming tissue tolerance has instantly normalised.

Begin or resume movement according to the treating clinician’s instructions and the individual response. Progress one variable at a time - range, volume, resistance or task complexity - and monitor the cumulative effect. A major night-pain flare or loss of function suggests excessive dosage, not proof that the patient must push harder.

When response is limited

A poor response should prompt review rather than automatic repetition. Reconsider the diagnosis, structural alternatives, diabetes and other comorbidity, treatment target, injection placement, symptom duration, rehabilitation dose and whether the outcome window was realistic. Lack of pain relief does not prove that hydrodilatation or surgery is necessarily the next step.

Where substantial pain and disability persist despite appropriate non-operative care, escalation can be discussed using local pathways and shared decision-making. The relative benefits, harms and costs of further procedures are addressed in the companion review on manipulation under anaesthesia and arthroscopic capsular release.

Implications for professional practice

1. Define the target and timeframe. Short-term pain relief is a more evidence-aligned goal than a guaranteed cure.
2. Explain what the procedure does and does not do. Avoid mechanically certain language about breaking all adhesions.
3. Treat guidance and outcome as related but distinct. Accurate placement does not guarantee a clinically important response.
4. Make diabetes planning explicit. Discuss temporary hyperglycaemia and provide an individual monitoring pathway.
5. Use the benefit window deliberately. Connect pain relief to sleep, function and tolerable progressive rehabilitation.
6. Review before repeating or escalating. Reconsider diagnosis, target, response and alternatives.